The Federal Reserve now needs to be on Trump watch if it wants to engineer the proper dose of monetary policy, according to Bank of America chief Brian Moynihan. "They've got a new administration with a new set of fiscal policies,

CNBC's Jim Cramer on Wednesday told investors there will be a shift in Wall Street's focus, from the actions of the Federal Reserve to those of President Donald Trump. "We're now looking at the changing of the guard from Powell to Trump," he said. "It won't be easy, as one's a pretty predictable guy and the other's a wild card."

President Donald Trump doesn’t like to wait, and patience is exactly what the Federal Reserve is serving right now. After December’s strong jobs report, the Fed seems comfortable sitting tight, keeping interest rates steady instead of cutting them.

President Donald Trump wasted no time in getting to work on his first day in office with a range of executive orders, but the fiscal house he’s inheriting may prove more challenging to fix.

• Establish the Department of Government Efficiency under the Executive Office of the President until July 4, 2026. This is the entity led by Elon Musk, the world’s richest man, and is charged with recommending cuts in federal programs and spending.

Several large U.S. financial institutions, including the Federal Reserve, have withdrawn from the networks after years of growing political and legal pressure.

Investors considering alternative strategies should proactively adjust their portfolios to anticipate these potential changes.

Democratic-led states and civil rights groups filed a slew of lawsuits challenging U.S. President Donald Trump's bid to roll back birthright citizenship on Tuesday in an early bid by his opponents to block his agenda in court.

President Trump said he was considering Feb. 1 as a start date for tariffs against Canada and Mexico, directing federal agencies to assess compliance with recent trade agreements.

Trump's VA pick, former Rep. Doug Collins, said the VA may be trying to fill positions, but many of those vacancies have gone unfilled for weeks or longer.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.